anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.

Adults: For Edema: The usual adult dosage is 25 to 100 mg daily as a single or divided dose. Many patients with edema respond to intermittent therapy, i.e., administration on alternate days or on 3 to 5 days each week. With an intermittent schedule, excessive response and the resulting undesirable electrolyte imbalance are less likely to occur. 

For Control of Hypertension: The usual initial dose in adults is 25 mg daily given as a single dose. The dose may be increased to 50 mg daily, given as a single or two divided doses. Doses above 50 mg are often associated with marked reductions in serum potassium (see also PRECAUTIONS). 

Patients usually do not require doses in excess of 50 mg of hydrochlorothiazide daily when used concomitantly with other antihypertensive agents.

Infants and Children: For Diuresis and for Control of Hypertension: The usual pediatric dosage is 0.5 mg to 1 mg per pound (1 to 2 mg/kg) per day in single or two divided doses, not to exceed 37.5 mg per day in infants up to 2 years of age or 100 mg per day in children 2 to 12 years of age. In infants less than 6 months of age, doses up to 1.5 mg per pound (3 mg/kg) per day in two divided doses may be required (See PRECAUTIONS: Pediatric Use).
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dermatology, trichology and cosmetology. Blood is taken by venipuncture into a sterile vacuum tube with an anticoagulant at a ratio of 10:1. First centrifugation of the tube is carried out for at least 5 minutes at 1,800 rpm. Then the plasma, leukocyte layer and the upper part of the erythrocyte layer is taken from the tube with a syringe of 5 ml with a needle of not more than 18G. This mixture is transferred to another vacuum sterile tube, which is then centrifuged for at least 8 minutes at 2,500 rpm. After that, 2 ml of plasma is taken into a 2–3 ml injection syringe containing 0.1 ml of 10 % calcium chloride solution in the ratio of calcium chloride:plasma 1:20 with a needle of no more than 18G placed by the lower end of the cut into the plasma layer 1 mm above the leukocyte film. Subsequent manual suspension is performed by inverting the syringe at least 10 times. Obtained autologous activated, platelet-rich plasma by the linear retrograde technique is injected in the form of injections over the entire surface of alopecia at the level of the lower layers of the dermis, 0.15 ml per injection. Such injections are carried out 1 time a month for 4 months with the possibility of repeating a similar course of treatment in the event of a relapse.EFFECT: method provides a high and fast effective effect in terms of hair density, thickness of hair rods and intensity of hair loss with preservation of the clinical result up to 16 months.1 cl, 2 dwg, 1 tbl, 2 ex
PURPOSE: To provide an aq. liposome system which contains at least one kind of phospholipids in addition to a nontoxic org. solvent, has particularly high stability and does not form undesirable precipitate. CONSTITUTION: The aq. liposome system contg. at least a kind of the phospholipids in addition to the nontoxic org. solvent additionally contains nonphospholipid substances. These nonphospholipid substances are bile acid, bile acid salt, the salts of the bile acid deriv. and/or bile acid salt deriv. The mass ratio of the phospholipids to the nonphospholipid substances changes between 1:0.001 to 0.1. Such liposome system is produced by dissolving or dispersing the phospholipid together with at least one kind of the substances of the nonphospholipid system at the mass ratio of 1:001 to 1:0.1 in the org. solvent and partially or completely evaporating the solvent from the soln. or dispersion, then adding water thereto.
The invention relates to a Chinese drug for calming endopathic wind and reducing blood pressure and a preparation method thereof. The Chinese drug is used for treating hypertension, encephalemia, hemiparalysis, limb and trunk paralysis, slurred speech or facial hemiparalysis, and is prepared as pills with cinnamon, achyranthes root, prepared rehmannia root, fructus toosendan, tortoise plastron, selfheal spike, capillary artemisia, white peony root, radix scrophulariae, asparagus root, malt, liquorice, oyster, leech 5, fossil teeth, skunk bush, goldthread root, medcinal evodia fruit, white atractylodes rhizome, uncaria, tuckahoe, gastrodia elata, ruddle, cortex eucommiae and parasitic loranthus. When being taken, the Chinese drug is boiled for 35-40 minutes in clean water, and the supernatant is used for preparing soup; or the Chinese drug is boiled for 5-10 minutes in clean water, dried and ground to powder, mixed in a tile basin, and stirred thoroughly and made into pills or capsules. The weight of each pill is about 6g, and the weight of each capsule is about 1g. The Chinese drug has the function of treating the hypertension, encephalemia, hemiparalysis, limb and trunk paralysis, slurred speech and facial hemiparalysis. The preparation method has the advantages of low manufacturing cost, simple process, fast absorption, high cure rate, less recurrence and no toxic side effect.
PURPOSE: A novel cosmetic formulation containing liposome with oxazolidin-2-one compounds is provided to improve skin permeability. CONSTITUTION: A cosmetic formulation for enhancing skin permeability contains: a wall formed from a double layer of amphiphilic lipid; and a liposome dispersion containing liposomes. The cosmetic formulation contains a capsulated cosmetic or dermatologically active formulation .The amphiphilic lipid is an ionic or non-ionic hydrophilic group. The wall of liposome is formed by lecithin or lysolecithin. A cosmetic or dermatological composition contains cosmetically or dermatologically acceptable excipient. The composition is an aqueous composition of lotion or serum.
PURPOSE:A healthy food capable of preventing and eliminating peptic ulcer, containing essence obtained by extracting a water-soluble substance from a mold belonging to the genus Volvariella of the family Amanitaceae as an active ingredient. CONSTITUTION:A healthy food containing essence obtained by extracting a water-soluble substance from a mold belonging to the genus Volvariella of the family Amanitaceae as an active ingredient. Volvariella volvacea (Fr)Sing may be naturally occurring one or artificially cultivated one and artificially cultivated one is practically used. The amount of water used in the extraction is sufficiently 0-10pts.wt. based on 1pt.wt. Volvariella volvacera (Fr)Sing. The prepared extracted essence contains a polysaccharide, nucleic acid, piptide, oligosaccharide, amino acid, salt, etc., has anti-peptic ulcer action and is useful for a solid substance for a healthy food or healthy drink. No toxicity is observed in 1.5g/kg(oral) administration by acute toxicity test on a mouse.
Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with clomipramine hydrochloride and should counsel them in its appropriate use. A patient Medication Guide about "Antidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts or Actions" is available for clomipramine hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking clomipramine hydrochloride.
These CE workshops will be mandatory for all partnership researchers who receive U54 funding in the proposed renewal period including Full, Pilot, and Developmental projects. The CE workshops are aimed to increase researchers' knowledge about the best strategies to establish teamwork with community members to achieve mutual benefits and advance translational research in cancer.
PURPOSE: Craniopharyngioma is a tumor derived from the squamous epithelium of Rathke's pouch. Despite successful excision, recurrence is common, typically occurring at the original tumor site. More rarely, recurrences can manifest at distant locations. This article reports on three distinct types of ectopic recurrence and reviews the existing literature.
METHODS: We reviewed clinical records and neuroimaging data of craniopharyngioma patients at our institution, identifying three cases of ectopic recurrence. Additionally, we conducted a literature review of similar cases published between 1975 and 2023, focusing on historical background, pathophysiology, clinical and radiological features, and treatment options.
RESULTS: We identified nineteen articles detailing ectopic recurrence of craniopharyngiomas in pediatric patients. The right frontal lobe was the most frequently reported site of recurrence. The shortest interval to recurrence was 11 months, while the longest was 14 years. Most cases were managed with surgical resection, yielding positive outcomes. In our cases, the recurrence sites were temporal intraparenchymal, intraosseous orbital, and occipital intraventricular. All were successfully treated with surgery, with no subsequent recurrences.
CONCLUSION: Although craniopharyngiomas are histologically benign, they can recur locally and, more rarely, at distant sites. Surgical intervention is generally well-tolerated. Further research into tumor cell dissemination mechanisms is essential to develop strategies for preventing ectopic recurrence.
General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
PCT No. PCT/KR92/00043 Sec. 371 Date Jul. 5, 1994 Sec. 102(e) Date Jul. 5, 1994 PCT Filed Sep. 18, 1992 PCT Pub. No. WO93/06107 PCT Pub. Date Apr. 1, 1993.The present invention relates to new ginkgolide derivatives of the formula (I) as below which represents PAF-antagonistic activity and the method for the preparation thereof, by that the cyclic compounds of substituted Ginkgolide B derivatives are produced by reacting the known Ginkgolide B and C mixture having the hydroxy group in 1- and 10-carbon with acid, then they are separated, and separated Ginkgolide B derivatives is hydrolyzed in acidic aqueous solution. And the present invention is related to make use it as PAF-antagonistic agent through separating the only one component of the new ginkgolide derivative by those methods.    <IMAGE>  (I)
Swallow deferasirox tablets once daily with water or other liquids, preferably at the same time each day. Take deferasirox tablets on an empty stomach or with a light meal (contains less than 7% fat content and approximately 250 calories). Examples of light meals include 1 whole wheat English muffin, 1 packet jelly (0.5 ounces), and skim milk (8 fluid ounces) or a turkey sandwich (2 oz. turkey on whole wheat bread w/ lettuce, tomato, and 1 packet mustard). Do not take deferasirox tablets with aluminum-containing antacid products [see Drug Interactions (7.1)]. For patients who have difficulty swallowing whole tablets, deferasirox tablets may be crushed and mixed with soft foods (e.g., yogurt or applesauce) immediately prior to use and administered orally. Commercial crushers with serrated surfaces should be avoided for crushing a single 90 mg tablet. The dose should be immediately and completely consumed and not stored for future use.

For patients who are currently on chelation therapy with deferasirox tablets for oral suspension and converting to deferasirox tablets, the dose should be about 30% lower, rounded to the nearest whole tablet. The table below provides additional information on dosing conversion to deferasirox tablets.
Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
Tablet for oral use. 1 tablet 6 times a day. The duration of Dietressa therapy is 24 weeks.
Migraine is a type of headache that lasts 4-72 hours, and it is characterized by throbbing pain on one side of the head, and recurrent attacks, making routine daily activities and movements difficult. Also, nausea and vomiting may accompany migraine, and sensitivity to both light and sound may increase. The World Health Organization (WHO) lists migraine as the disease that causes the most disability.

Approaches to the treatment of migraine consist of pharmacological and non-pharmacological treatments. Within the scope of non-pharmacological approaches, it is aimed to increase the coping skills of the individual by using methods such as exercise, stress management, and cognitive behavioral therapy, which include physical, mental, and cognitive interventions. Although these approaches are effective respectively, since migraine affects the whole life of the individual, there is a need for applications in which the approaches are applied with a combined and individual perspective. It has been shown that coping skills training improves both the physical and mental health and well-being of individuals with chronic headaches. It is known to cause a decrease in pain intensity, migraine attacks, and drug use. At the same time, it is aimed to adapt the individual to live efficiently. Despite these positive effects, there is a limited number of studies examining the effect of migraine coping skills training on individuals' disabilities and coping skills. Therefore, within the scope of this study, the effects of client-centered coping skills training on pain, disability, coping skills, and quality of life were examined.
The invention relates to a multifunctional synergistic pharmaceutical composition based on adriamycin. The natural hydrophobic micromolecules with conjugated structures are covalently coupled to polysaccharide skeletons to form the anti-angiogenesis medicine, the anti-angiogenesis medicine is physically mixed with the mitochondria damage peptide derivatives modified by the conjugated structures and the adriamycin, and the medicine composition with the nanometer size is assembled by means of various supermolecule driving forces. The pharmaceutical composition has the characteristics of simultaneously regulating and controlling a tumor microenvironment and tumor cells, reversing the apoptosis resistance of the tumor cells and maximizing the anti-tumor effect of the adriamycin. In addition, the adriamycin conjugate has the advantages of high adriamycin load, high stability and strong targeting property. The adriamycin-based multifunctional synergistic pharmaceutical composition can be prepared into an anti-tumor pharmaceutical preparation for injection, oral administration or external use by being compatible with corresponding pharmaceutical excipients. The invention is prepared by a method of multi-component medicine supermolecule combination construction, has simple operation and is easy to realize industrial production.
Presence of moderate renal impairment (eGFR 30-59 mL/min/1.73m2). Subjects will receive 1 dose of ISIS 681257.
Psoriasis is a chronic autoimmune disease with a long disease course and frequent relapse characteristics. It is now recognised to be associated with epidermal environments of inflammatory cytokines. However, its pathogenesis is still not completely clear. We found the haemorheology of psoriatic patients to be abnormal, and ageing and deformed erythrocytes increased in the blood. The abnormal erythrocytes were more likely to induce psoriasis, which was confirmed in a mouse model induced by different blood components of psoriatic patients/healthy volunteers. Spleen filtration dysfunction, which caused abnormal erythrocytes, was also more likely to induce psoriasis, which was confirmed in a mouse model induced by splenectomy. The mechanism was the weakening of the 'eat me' function of spleen macrophages phagocytizing ageing and deformed erythrocytes, resulting in the dysfunction of spleen filtration and the increase of ageing and deformed erythrocytes in the body. Additionally, the decreased oxygen-carrying capacity and the declined antioxidant capacity of those erythrocytes led to the hypoxia environment, making psoriasis more likely to be induced. These findings demonstrate that spleen filtration dysfunction contributes to the pathogenesis of psoriasis and suggest that improving it may be an effective therapy for psoriasis and control its relapse.
Participants in the electroacupuncture group received acupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36). After skin disinfection, sterile adhesive pads were placed on these acupoints, and acupuncture needles were inserted through the adhesive pads approximately 50 to 60 mm into the skin. Paired electrodes from the electroacupuncture apparatus were attached to the needle handles of Xuanji (CV21) and Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), bilateral Liangmen (ST21), and bilateral Zusanli (ST36). The electroacupuncture stimulation lasted for 30 minutes with an intermittent wave of 50 Hz and a current intensity of 1 to 5mA (preferably with the skin around the acupoints shivering mildly without pain). Participants received 1 treatment session per day until the success of ventilator weaning (up to 21 days).
Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
The present invention provides a dispersible tablet for treating blood syndromes, which is formed by using the extract of Callicarpa nudiflora Hook. Et Arn. as active ingredients, and supplementary materials used for the dispersible tablet. According to moisture-free rutin C27H30O16, the content of total flavonoids is not smaller than 29.50 mg for each tablet. The dispersible tablet of the present invention has the advantages of uniform dispersion, quick disintegration, the elimination of saline taste of the Callicarpa nudiflora Hook. Et Arn., favorable mouth feelings, convenient administration, uniform dispersion, stable quality and favorable controllability, and the leaching quantity of the total flavonoids is greater than 70% within 10 minutes.
The present application discloses compositions and methods of use of dual-labeled molecules comprising a fluorescent probe and a radionuclide. The labeled molecules are of use for detection, imaging and/or diagnosis of diseased tissues, such as tumors. In preferred embodiments, the dual-labeled molecules are of use in pre-operative and/or intraoperative imaging, for example to detect margins of malignant tissues to facilitate surgical resectioning. In more preferred embodiments, a radioprotective agent such as an oxygen radical scavenger is used to decrease radiolysis of the fluorescent signal. The labeled molecules bind to a disease-associated antigen, such as a tumor-associated antigen. Exemplary molecules include antibodies, antibody fragments, bispecific antibodies, targetable constructs and targeting peptides, such as bombesin analogues.
BACKGROUND: Splenomegaly can exacerbate liver cirrhosis and portal hypertension. We have previously demonstrated that cyclooxygenase-2 (COX-2) inhibitor can attenuate cirrhotic splenomegaly. However, the mechanism of cirrhotic splenomegaly remains unclear, thus becoming the focus of the present study.
MATERIALS AND METHODS: Thioacetamide (TAA) intraperitoneal injection was used to induce cirrhotic splenomegaly. Rats were randomized into the control, TAA and TAA + celecoxib groups. Histological analysis and high-throughput RNA sequencing of the spleen were conducted. Splenic collagen III, α-SMA, Ki-67, and VEGF were quantified.
RESULTS: A total of 1461 differentially expressed genes (DEGs) were identified in the spleens of the TAA group compared to the control group. The immune response and immune cell activation might be the major signaling pathways involved in the pathogenesis of cirrhotic splenomegaly. With its immunoregulatory effect, celecoxib presents to ameliorate cirrhotic splenomegaly and liver cirrhosis. Furthermore, 304 coexisting DEGs were obtained between TAA vs. control and TAA + celecoxib vs. TAA. Gene ontology (GO) and KEGG analyses collectively indicated that celecoxib may attenuate cirrhotic splenomegaly through the suppression of splenic immune cell proliferation, inflammation, immune regulation, and fibrogenesis. The impacts on these factors were subsequently validated by the decreased splenic Ki-67-positive cells, macrophages, fibrotic areas, and mRNA levels of collagen III and α-SMA.
CONCLUSIONS: Celecoxib attenuates cirrhotic splenomegaly by inhibiting splenic immune cell proliferation, inflammation, and fibrogenesis. The current study sheds light on the therapeutic strategy of liver cirrhosis by targeting splenic abnormalities and provides COX-2 inhibitors as a novel medical treatment for cirrhotic splenomegaly.
Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
BACKGROUND: For renal stones > 20 mm, percutaneous nephrolithotomy (PNL) offers the best stone clearance rates with acceptable complication rates. This study aimed to compare the efficiency of high-power holmium YAG laser and ballistic lithotripsy during mini-PNL.
METHODS: Data from 880 patients who underwent mini-PNL for renal stones was investigated retrospectively. The study utilized propensity score matching to create two groups: laser lithotripsy (n = 440) and ballistic lithotripsy (n = 440). The groups were matched based on stone size, Guy's stone score, and stone density. The main objectives of the study were to assess the stone-free rate (SFR), duration of surgery, and complication rates.
RESULTS: The average age of the population was 51.4 ± 7.1 years, with a mean stone size of 28.6 ± 8.3 mm and a mean stone density of 1205 ± 159 HU. There were no significant differences between the groups. The SFRs of the laser lithotripsy and ballistic lithotripsy were 92.5% and 90.2%, respectively (p = 0.23). The laser lithotripsy group had a notably shorter surgery time (40.1 ± 6.3 min) compared to the ballistic lithotripsy group (55.6 ± 9.9 min) (p = 0.03). Complication rates were similar (p = 0.67).
CONCLUSIONS: Our study shows that a high-power holmium YAG laser provides quicker operation time compared to ballistic lithotripsy. However, ballistic lithotripsy is still an effective and safe option for stone fragmentation during mini-PNL. In places where a high-power holmium YAG laser is not available, ballistic lithotripters are still a safe, effective, and affordable option for mini-PNL.